In myeloma treatment, acute CRS is a common but treatable AE associated with CAR T-cell therapy and bispecific antibodies, ...
Siltuximab effectively treated patients who experienced common adverse events after chimeric antigen receptor T-cell therapy, ...
MedPage Today on MSN12d
T-Cell Rebalancing Therapy Active in Previously Treated Atopic DermatitisTreatment-emergent adverse events (TEAEs) occurred in a similar proportion of patients in each group, and were mostly mild or ...
Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...
The analysis encompassed safety outcomes including cytokine release syndrome and immune ... CNS-directed therapy during bridging before CAR T-cell therapy, including radiotherapy alone ...
Our blood consists of many cell types that develop through different stages from a precursor type—the blood stem cell. An ...
Oncologists are increasingly favoring CAR T-cell therapy’s early-line use in relapsed/refractory multiple myeloma despite ...
The data from the Phase 1/1b clinical trial of soquelitinib in patients with T cell lymphoma continues to demonstrate strong indications of anti-tumor activity in a significant number of patients,” ...
Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced ...
During a live event, John L. Wagner, MD, moderated a discussion on when to refer patients for CAR T-cell therapy and what ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback